Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

Appointment of Chief Financial Officer

10 July 2023 Allergy Therapeutics plc (AIM: AGY), the integrated commercial biotechnology company specialising in allergy vaccines, is pleased to announce the promotion of Shaun Furlong to Chief Financial Officer (CFO) with effect from 11 August, when the current interim CFO, Martin Hopcroft, will leave the Company.

Shaun brings significant financial experience in both technical and commercial roles. He joined Allergy Therapeutics as Group Financial Controller and a member of the Group's senior management team in April 2022. He previously held senior finance roles within blue-chip companies across multiple sectors, including Legal & General, Hastings Direct, Volution Group and American Express. He is a Fellow of the Institute of Chartered Accountants in England and Wales, and holds a PhD in polymer chemistry from the University of Sussex.

Manuel Llobet, Chief Executive Officer, said: "I have had the pleasure of working with Shaun for some time in his role as Group Financial Controller for the Company and know him to be highly diligent and professional with strong business acumen, so am delighted to welcome him in his new role. I also want to take this opportunity to thank Martin Hopcroft for his expertise and commitment during his time as interim CFO over recent months and wish him the best for the future."

Shaun Furlong, incoming Chief Financial Officer, said: "I am excited to step into my new role as CFO of Allergy Therapeutics, a pioneering company shaping the future of innovative immunotherapies. Leveraging my industry experience, I look forward to working with the leadership team."

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

+44 (0)1903 845 820

Panmure Gordon (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

Consilium Strategic Communications

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.